BBOpCo at AACR 2026: First-Line BOT/BAL in Selected MSS Colorectal Cancer Population

The Shift Toward Anatomically Informed Patient Selection

For years, microsatellite stable (MSS) colorectal cancer has been the “white whale” of immunotherapy. Because these tumors are immunologically “cold,” they typically ignore the signals that tell the immune system to attack. The traditional approach was to treat the entire MSS population with the same heavy-hitting chemotherapy, regardless of where the cancer had spread.

However, a new trend is emerging: anatomical patient selection. The BBOpCo study suggests that the location of metastases matters. By specifically selecting patients without liver, bone, or brain metastases, clinicians may be identifying a subgroup that is more responsive to immune checkpoint blockade.

This shift moves us away from a “one size fits all” model and toward a more nuanced strategy. If certain anatomical sites act as “immune sinks” or barriers to therapy, excluding them could be the key to unlocking the potential of immunotherapy in previously untreatable populations.

Rethinking the Sequence: Immunotherapy Before Chemotherapy

The standard of care for metastatic MSS colorectal cancer has long been sequential chemotherapy. While effective, this often leads to prolonged toxicities and eventual disease progression. The emerging trend is to flip the script: using immunotherapy as the first-line defense to delay or even avoid chemotherapy.

The data from the BBOpCo study provides a compelling proof-of-concept. In a small cohort of 15 patients, the combination of botensilimab (BOT) and balstilimab (BAL) achieved a disease control rate (DCR) of 71%.

Perhaps more significant is the median freedom from crossover to chemotherapy of 8.7 months. This suggests that a “chemo-delay” strategy is not only feasible but potentially beneficial, offering patients a window of time to maintain quality of life before resorting to more aggressive cytotoxic treatments.

For more on advanced trials in this space, explore the Phase 3 BATTMAN Trial in MSS or pMMR Metastatic Colorectal Cancer.

Turning “Cold” Tumors “Hot” with Dual Blockade

The future of treating MSS CRC likely lies in synergistic combinations. A single agent is rarely enough to wake up a “cold” tumor. The BOT/BAL combination represents a dual-pronged attack:

• Botensilimab (BOT): An Fc-enhanced anti-CTLA-4 antibody that primes and expands T-cells while reducing regulatory T-cells that protect the tumor.
• Balstilimab (BAL): A PD-1 inhibitor that restores the T-cell’s ability to recognize and kill cancer cells.

By combining early immune activation (BOT) with sustained inhibition (BAL), this approach aims to transform the tumor microenvironment from an immune desert into a site of active combat. This strategy is being explored across other difficult-to-treat cancers, including PD-1 refractory gastroesophageal cancer.

The Role of Precision Biomarkers in Future Care

We are moving toward an era where we won’t just look at where the cancer is, but exactly what it looks like under a microscope. Exploratory analyses using multiplex immunohistochemistry are already revealing why some patients respond while others don’t.

Key markers identified in early data include:

• Responders: Showed increased infiltration of cDC1s (conventional dendritic cells), which are crucial for presenting tumor antigens to T-cells.
• Non-responders: Exhibited higher Spp1/CXCL9 macrophage ratios, suggesting a more suppressive environment.

In the future, these biomarkers could be used to screen patients before they even begin therapy, ensuring that the right patients receive the BOT/BAL combination while others are steered toward alternative treatments.

Frequently Asked Questions

What is the difference between MSS and MSI colorectal cancer?
MSS (Microsatellite Stable) tumors have a functional DNA mismatch repair system, making them “cold” and less responsive to standard immunotherapy. MSI (Microsatellite Instability) tumors have errors in this system, making them “hot” and generally more responsive to PD-1 inhibitors.

Why exclude liver metastases in the BBOpCo study?
Prior data indicated a higher disease control rate (73%) in patients without liver metastases, suggesting that the liver microenvironment may inhibit the effectiveness of the BOT/BAL combination.

Is the BOT/BAL combination safe?
The safety profile is consistent with other checkpoint inhibitors. While Grade 3 toxicities (primarily colitis) occurred, no Grade 4 toxicities or treatment-related deaths were reported in the BBOpCo study due to proactive management.

To stay updated on the latest developments in immunotherapy, visit the official Agenus website.